Home › Funds › BNP Paribas Asset Management Holding S.A. › VRTX

BNP Paribas Asset Management Holding S.A. position in VRTX

VERTEX PHARMACEUTICALS INC · Health Care

BNP Paribas Asset Management Holding S.A. reported holding 886,431 shares of VRTX (VERTEX PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$463.4M, representing 0.47% of its reported portfolio and ranking #33 among its reported holdings. BNP Paribas Asset Management Holding S.A. has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)886.43K sh
Reported value held$463.45M
Portfolio Weight0.47%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How BNP Paribas Asset Management Holding S.A.'s VRTX position evolved

BNP Paribas Asset Management Holding S.A. first disclosed a stake in VRTX in Q3 2023 at 690,148 shares (US$240.0M). The position peaked in Q3 2026 at 886,431 shares, worth US$463.4M. Across 13 filings, BNP Paribas Asset Management Holding S.A. increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 886,431 shares valued at US$463.4M — a reduction of -11,462 shares quarter over quarter.. Notable position changes include a 47% increase in Q4 2025 (shares fell 1% over the following quarter), a 27% increase in Q1 2026 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 690.15K $239.99M New
Q4 2023 601.51K $244.75M Reduce
Q1 2024 486.88K $203.52M Reduce
Q2 2024 407.61K $191.06M Reduce
Q3 2024 396.02K $184.18M Reduce
Q4 2024 389.66K $156.91M Reduce
Q1 2025 392.01K $190.11M Add
Q2 2025 444.46K $197.77M Add
Q3 2025 456.33K $178.59M Add
Q4 2025 669.81K $303.72M Add
Q1 2026 848.05K $378.71M Add
Q2 2026 897.89K $446.04M Add
Q3 2026 886.43K $463.45M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About VRTX and 13F data

VRTX (VERTEX PHARMACEUTICALS INC) is a Health Care company. 32 other funds we track also report a position in VRTX — the largest reported positions include Capital World Investors (US$13.58B), Capital World Investors (US$12.97B), Capital Research Global Investors (US$9.68B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding VRTX

All VRTX fund holders →

FAQ

How long has BNP Paribas Asset Management Holding S.A. held VRTX?

BNP Paribas Asset Management Holding S.A. has disclosed VRTX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is BNP Paribas Asset Management Holding S.A.'s current position in VRTX?

As of Q3 2026, BNP Paribas Asset Management Holding S.A. holds 886.43K shares of VRTX (VERTEX PHARMACEUTICALS INC), valued at $463.45M, representing 0.47% of its reported portfolio and ranking #33.

Has BNP Paribas Asset Management Holding S.A. been buying or selling VRTX?

In the latest 13F filing (Q3 2026), BNP Paribas Asset Management Holding S.A. reduced its position in VRTX. The position peaked in Q3 2026 at 886.43K shares.

Which other funds hold VRTX?

Other major institutional holders of VRTX include Capital World Investors, Capital World Investors, Capital Research Global Investors, among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.